Skip to main content
SpringerLink
Log in

Fluvastatin (lescol) treatment of hyperlipidaemia in patients with renal transplants

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Hyperlipidaemia of 18 male and 20 female patients following successful renal transplantation was treated with daily 20 mg fluvastatin (Lescol) for 12 weeks. The patients were several months after transplantation, and their total cholesterol levels exceeded 6.5 mmol/l following an 8-week diet. The effect of fluvastatin on the levels of total cholesterol, HDL, LDL, triglyceride, Apo A1 and Apo B, as well as of lipoprotein(a) was examined. Furthermore, changes of the renal function (GFR-urea, creatinine, uric acid) and hepatic function (bilirubin, GOT, GPT, CPK, ALP) were followed up, together with the body weight and blood pressure.

The results of the examinations are summarized as follows: Fluvastatin may be administered effectively and without side effects in a daily dose of 20 mg in appropriately selected renal transplant patients. The average total cholesterol values, which were 7.91 mmol/l in men and 7.78 mmol/l in women following the diet, were reduced by 22–25% (p<0.001) after 6 and 12 weeks, respectively, of fluvastatin treatment. The levels of LDL also decreased significantly (p<0.001): in response to a 20 mg evening dosage, reduction of more than 25% was observed in 78% of men and 65% of women. Reductions of the Apo B levels were more pronounced in the females (18.3% men vs. 21.2% women).

The ratio C/HDL-C decreased both in men (from 5.49 to 4.19) and in women (from 4.83 to 4.02). The ratio Apo B/Apo A1 also decreased (men: from 0.86 to 0.73, women: from 0.73 to 0.66). The concentrations of HDL and Apo A1 did not increase significantly, the reductions in the levels of triglyceride and lipoprotein(a) were not considerable either. An increase in the levels of hepatic enzymes and CPK was not encountered during the administration of fluvastatin. In two patients the levels of serum bilirubin increased by 2–4 μmol/l. Three patients complained about temporary myalgias of the sacroiliac or lumbar region which, however, were not accompanied by elevated CPK levels. The monitored levels of cyclosporine, urea and creatinine did not increase significantly during the 12 weeks of treatment. Two patients had temporary gastric complaints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bortman, G., Sellanes, M., Odell, D. S., Ring, W. S., Olivari, M. T.: Discrepancy between prae and post transplant diagnosis of end-stage dilated cardiomyopathy.Amer. J. Cardiol., 74, 921 (1994).

    Article  PubMed  CAS  Google Scholar 

  2. Casteleo, A. M., Grino, J. M., Andres, E., Seros, D., Castineira, M. J., Roca, M., Morero, F., Atalau, J.: HMG-Co-A reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporin A immunosuppression. XIIth Intern. Congr. of Nephrology, Jerusalem, June 13–18, 1993. Abstr. pp. 512.

  3. Cosio, F. G., Dillon, J. J., Falkenhain, E., Tesi, J., Henry, M. L., Elkhammas, E. A., Davies, E. A., Bumgardner, G. L., Ferguson, R. M.: Racial differences in renal allograft survival: The role of systemic hypertension.Kidney Int. 47, 1136 (1995).

    PubMed  CAS  Google Scholar 

  4. Desylpere, J. P.: The role of HMG-Co-A reductase inhibitors in the treatment of hyperlipidaemia: A review of fluvastatin.Curr. Therap. Res., 56, 112 (1995).

    Google Scholar 

  5. Ghods, A. J., Milanian, I., Arghani, H., Ghadiri, G.: The efficacy and safety of fluvastatin in hypercholesterolemia of renal transplant recipients. XXXIInd Eur. Dial. Transpl. Ass. Cong. Athens 1995. June 11–14. Abstr. pp. 303.

  6. Goldberg, R. B., Roth, D.: A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.Amer. J. Cardiol.,76, Suppl. 107A (1995).

  7. Harnett, J. D., Foley, R. N., Kent, G. M., Barre, P. E., Murray, D., Parfrey, P. S.: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors.Kidney Int., 47, 884 (1995).

    PubMed  CAS  Google Scholar 

  8. Holdaas, H., Hartmann, A., Sentrom, J., Dahl, K. J., Borge, M., Pfister, P.: Fluvastatin safety lowers atherogenic lipids in renal transplant patients receiving cyclosporine.Amer. J. Cardiol.,76, Suppl. 102A (1995).

  9. Kasiske, B. L.: Risk factors for cardiovascular disease after renal transplantation.Miner. Electrolyte Metab., 19, 186 (1993).

    PubMed  CAS  Google Scholar 

  10. Keane, W. F.: Lipids and the kidney.Kidney Int., 46, 910 (1994).

    PubMed  CAS  Google Scholar 

  11. Levy, R. I., Troendle, A. J., Fattu, J. M.: A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG-Co-A reductase inhibitor fluvastatin.Circulation, 87, S-III, 45 (1993).

    Google Scholar 

  12. Li, P. K. T., Mak, T. W. L., Wang, A. Y., Lee, Y. T., Leung, C. B., Lui, S. F., Lam, C. W. K., Lai, K. N.: The interaction of fluvastatin and cyclosporine A in renal transplant patients with dyslipoproteinaemia.Int. J. Clin. Pharmacol. Ther., 33, 246 (1995).

    PubMed  Google Scholar 

  13. Manske, C. L., Kasiske, B. L.: Lipid abnormalities after renal transplantation. In: Keane, W. F., Stein, J. H. (eds.): Contemporary Issues in Nephrology. Vol. 24. Lipids and Renal Disease. Churchill Livingstone, New York 1992, pp. 37–61.

    Google Scholar 

  14. Nishizawa, Y., Shoji, T., Nishitani, H., Yarmakawa, M., Konishi, T., Kawasaki, K., Morri, H.: Hypertriglyceridaemia and lowered apolipoprotein CII/CIII ratio in uremia. Effect of fibric acid, clinofibrate.Kidney Int., 44, 1352 (1993).

    PubMed  CAS  Google Scholar 

  15. Nilsson, J.: Lipid oxidation, vascular inflammation and coronary atherosclerosis.Transplant. Proc., 25, 2063 (1993).

    PubMed  CAS  Google Scholar 

  16. Reade, V., Tailleux, A., Reade, R., Harduin, P., Cachera, C., Tacquet, A., Fruchart, J. C., Fievet, C.: Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients.Kidney Int., 44, 1360 (1993).

    PubMed  CAS  Google Scholar 

  17. Samuelson, O., Aurell, M., Knight-Gibson, Attman, P. Q.: Apolipoprotein B containing lipoproteins and the progression of renal insufficiency.Nephron, 63, 279 (1993).

    Google Scholar 

  18. Traindl, O., Reading, S., Franz, M., Watschinger, B., Klauser, R., Klauser, R., Pidlich, H., Widhalm, K., Pohanka, E., Kovarik J.: Treatment of hyperlipidemic kidney graft recipients with lovastatin: Effect on LDL-cholesterol and lipoprotein(a).Nephron, 62, 394 (1992).

    Article  PubMed  CAS  Google Scholar 

  19. Wang, C., Salahuddeen, K., McClain, M., Whitehead, J.: Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E.Kidney Int., 47, 927 (1995).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Medicine, University Medical School, Debrecen, Hungary

    L. Löcsey

  2. 1st Department of Surgery, University Medical School, Debrecen, Hungary

    L. Asztalos, Zs. Kincses & Gy. Balázs

Authors
  1. L. Löcsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Asztalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zs. Kincses
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gy. Balázs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Löcsey, L., Asztalos, L., Kincses, Z. et al. Fluvastatin (lescol) treatment of hyperlipidaemia in patients with renal transplants. International Urology and Nephrology 29, 95–106 (1997). https://doi.org/10.1007/BF02551424

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02551424

Keywords

Search

Navigation